We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+20.96%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$776M
AUM Growth
+$47.7M
Cap. Flow
-$46.2M
Cap. Flow %
-5.95%
Top 10 Hldgs %
74.59%
Holding
30
New
4
Increased
13
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$23.8M
2
AKRX
Akorn Inc
AKRX
+$19.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$12.9M
4
TVTX icon
Travere Therapeutics
TVTX
+$10.5M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$10.1M

Top Sells

Rank Stock Value
1
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$47.9M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$44.6M
3
HMSY
HMS Holdings Corp.
HMSY
+$17.2M
4
RLYP
RELYPSA INC COM
RLYP
+$13.9M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 71.6%
2 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
– –
-71,928
Closed -$6.7M
MACK
27
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-195,340
Closed -$13.5M
RLYP
28
DELISTED
RELYPSA INC COM
RLYP
– –
-660,462
Closed -$13.9M
AUXL
29
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-1,493,560
Closed -$44.6M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Consonance Capital Management held 30 positions worth $776M, up 6.6% from $729M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Consonance Capital Management withdrew a net $46.2M in Q4 2014, closing 6 positions and reducing 5 holdings. Its most notable exit was Taro Pharmaceutical Industries Ltd., an estimated $47.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 68% a quarter earlier, followed by Industrials.

Against the trend, Consonance Capital Management opened a new position in ADMA Biologics worth $9.8M.

  • Consonance Capital Management's largest Q4 2014 buy was ADMA Biologics: 877,407 shares worth $9.8M.
  • Consonance Capital Management added most to ANI Pharmaceuticals in Q4 2014, an estimated $23.8M increase.
  • Consonance Capital Management's biggest Q4 2014 reduction was HMS Holdings Corp., cutting an estimated $17.2M.
  • Consonance Capital Management fully exited Taro Pharmaceutical Industries Ltd. in Q4 2014, selling an estimated $47.9M.
  • Consonance Capital Management's ten largest holdings make up 75% of its $776M portfolio in Q4 2014.
  • Consonance Capital Management opened 4 new positions and closed 6 in Q4 2014.
  • Consonance Capital Management's portfolio value rose 6.6% quarter-over-quarter to $776M.

Based on Consonance Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.